Pharmacologic approaches to protection against radiation-induced lethality and other damage

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 6, 1997, Pages 1473-1478

  Weiss, Joseph F ^a  

^a U S DEPARTMENT OF ENERGY   (United States)

Author keywords

Aminothiols; Antioxidants; Eicosanoids; Growth factors; Radioprotection; Receptor mediated protection; Toxicity; WR 151327; WR 2721

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; ANTIOXIDANT; CYTOKINE; DNA; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; LIPID; PHOSPHOROTHIOIC ACID; PHOSPHOROTHIOIC ACID S 3 (3 METHYLAMINOPROPYLAMINO)PROPYL ESTER; POLYAMINE; THIOL DERIVATIVE;

CANCER; CANCER RADIOTHERAPY; CLINICAL RESEARCH; CONFERENCE PAPER; DNA STRUCTURE; DNA SYNTHESIS; DRUG MECHANISM; DRUG TOLERANCE; EMERGENCY MEDICINE; HUMAN; LETHALITY; LONG TERM EXPOSURE; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEAR ACCIDENT; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION ACCIDENT; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; SPACE FLIGHT; STEM CELL; STRUCTURE ACTIVITY RELATION; TISSUE INJURY; TOXICITY;

EID: 0031474070     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s61473     Document Type: Conference Paper

References (71)

1. Patt HM, Tyree EB, Straube RL, Smith DE. Cysteine protection against x-irradiation. Science 110:213-214 (1949).
2. Sweeney TR. A Survey of Compounds from the Antiradiation Drug Development Program of the U.S. Army Medical Research Development Command. Washington:Walter Reed Army Institute of Research, 1979.
3. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Radiation Sensitizers, Their Use in the Clinical Management of Cancer (Brady LW, ed). New York:Masson, 1980;309-320
4. Kligerman MM, Turrisi AT, Urtasun RC, Norfleet AL, Phillips TL, Barkley T, Rubin T. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 14:1119-1122 (1988).
5. Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experience. Eur J Cancer 31A(Suppl 1):S8-S13 (1995).
6. Ilyin LA. Chernobyl: Myth and Reality. Moscow:Megapolis, 1995.
7. Brown DQ, Graham WJ, MacKensie LJ, Pittock JW, Shaw L. Can WR-2721 be improved upon? Pharmacol Ther 39:157-168 (1988).
8. Holwitt EA, Koda E, Swenberg CE. Enhancement of topoisomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278. Radiat Res 124:107-109 (1990).
9. Grdina DJ, Shigematsu N, Dale P, Newton GL, Aguilera JA, Fahey RC. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 16:767-774 (1995).
10. Savoye C, Swenberg C, Hugot S, Sy D, Sabattier R, Charlier M, Spotheim-Maurizot M. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug Ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol 71:193-202 (1997).
11. Browne D, Pillai MV, MacVittie TJ, Weiss JF. Treatment of Radiation Injuries. New York:Plenum Press, 1990.
12. MacVittie TJ, Weiss JF, Browne D. Advances in the Treatment of Radiation Injuries. Oxford:Pergamon, 1996.
13. Foye WO. Radiation-protective agents in mammals. J Pharmaceut Sci 58:283-300 (1969).
14. Foye WO. Radioprotective drugs. In: Burger's Medicinal Chemistry (Wolff ME, ed). New York:John Wiley & Sons, 1981;11-45.
15. Giambarresi L, Jacobs AJ. Radioprotectants. In: Military Radiobiology (Conklin JJ, Walker RI, eds). Orlandor:Academic Press, 1987;265-301.
16. Weiss JF and Kumar KS. Antioxidant mechanisms in radiation injury and radioprotection. In: Cellular Antioxidant Defense Mechanisms, Vol II (Chow CK, ed). Boca Raton, FL:CRC Press, 1988:163-189.
17. Livesey JC, Reed DJ, Adamson LF. Radiation-protective Drugs and Their Reaction Mechanisms. Park Ridge, NJ:Noyes Publications, 1985.
18. Weiss JF, Simic MG. Perspectives in radioprotection. Pharmacol Ther 39:1-414 (1988).
19. Monig H, Messerschmidt O, Streffer C. Chemical radioprotection in mammals and in man. In: Radiation Exposure and Occupational Risks (Scherer E, Streffer C, Trott K-R, eds). Berlin:Springer-Verlag, 1990;97-143.
20. Murray D, McBride WH. Radioprotective agents. In: Kirk-Othmer Encyclopedia of Chemical Technology, 4th ed, Vol 20. New York:John Wiley & Sons, 1996;963-1006.
21. Bump EA, Malaker K. Radioprotectors: Chemical, Biological and Clinical Perspective. Boca Raton, FL:CRC Press, 1997.
22. Yuhas JM, Storer JB. Chemoprotection against three modes of radiation death in the mouse. Int J Radiat Biol 15:233-237 (1973).
23. Weiss JF, Landauer MR, Gunter-Smith PJ, Hanson WR. Effect of radioprotective agents on survival after acute intestinal radiation injury. In: Radiation and the Gastrointestinal Tract (Dubois A, King GL, Livengood DR, eds). Boca Raton, FL:CRC Press, 1995;183-199.
24. Bogo V, Jacobs AJ, Weiss JF. The behavioral toxicity and efficacy of WR-2721 as a radioprotectant. Radiat Res 104:182-190 (1985).
25. Bogo V. Behavioral radioprotection. Pharmacol Ther 39:73-78 (1988).
26. Landauer MR, Davis HD, Kumar KS, Weiss JF. Behavioral toxicity of selected radioprotectors. Adv Space Res 12(2):273-283 (1992).
27. Landauer MR, Davis HD, Dominitz JA, Weiss JF. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Pharmacol Biochem Behav 27:573-576 (1987).
28. Fleckenstein L, Swynnerton NF, Ludden TM, Mangold DJ. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors. Pharmacol Ther 39:203-212 (1988).
29. Weiss JF, Kumar KS, Srinivasan V and Landauer MR. Comparison of toxicity and radioprotective efficacy of WR-2721 and WR-3689. Proc Am Assoc Cancer Res 31:433 (1990).
30. Weiss JF, Kumar KS, Waiden TL, Neta R, Landauer MR, Clark EP. Advances in radioprotection through the use of combined agent regimens. Int J Radiat Biol 57:709-722 (1990).
31. Srinivasan V, Weiss JF. Radioprotection by vitamin E: injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice. Int J Radiat Oncol Biol Phys 23:841-845 (1992).
32. Benson KA, Landauer MR, Hogan JB, Shehata CW, Castro CA, Weiss JF. Propranolol enhances the radioprotective efficacy and reduces the behavioral toxicity of WR-1 51327 [abstract]. In: 42nd Annual Meeting of the Radiation Research Society, 29 April-4 May, 1994, Nashville, Tennessee. Oak Brook, Il:Radiation Research Society, 1994;211.
33. Landauer MR, Hogan JB, Castro CA, Benson KA, Shehata CW, Weiss JF. Behavioral toxicity and radioprotective efficacy of WR-151327 in combination with adenosine receptor antagonists. In: Proceedings of the 1995 ERDEC Scientific Conference on Chemical and Biological Defense Research 14-17 November 1995, Aberdeen Proving Ground, Maryland (Berg DA, ed). Aberdeen Proving Ground, MD:Research and Technology Directorate, 1996;665-669.
34. Swenberg CE, Landauer MR, Weiss JF. Radiomodification by caffeine alone and in combination with phosphorothioates: in vivo and cell-free studies. Radioprotection 32(C1):127-131 (1997).
35. Ryan SV, Carrithers SL, Parkinson SJ, Skurk C, NUSS C, Pooler PM, Owen CS, Lefer AM, Waldman SA. Hypotensive mechanisms of amifostine. J Clin Pharmacol 36:365-373, 1996.
36. Liu WF, Shih JH, Lee JD, Ma C, Lee SF, Lin CH. Effect of the radioprotector WR-2721 on operant behavior in the rat. Neurotoxicol Teratol 11:199-204 (1989).
37. Bogo V, Franz CG, Jacobs AJ, Weiss JF, Young RW. Effects of ethiofos (WR-2721) and radiation on monkey visual discrimination performance. Pharmacol Ther 39:93-95 (1988).
38. McDonough JH, Mele PC, Franz CG. Comparison of behavioral and radioprotective effects of WR-2721 and WR-3689. Pharmacol Biochem Behav 42:33-243 (1992).
39. 60Co by WR-2721 and WR-151327. Radiat Res 106:224-233 (1986).
40. Steel-Goodwin L, Kendrick JM, Egan JE, Eckstein JM. Pathological evaluation of WR-151327 administered orally in irradiated and non-irradiated male mice. Ann Clin Lab Sci 22:182-188 (1992).
41. Milas L, Hunter N, Stephens LC, Peters LJ. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 44:5567-5569 (1984).
42. Grdina DJ, Carnes BA, Grahn D, Sigdestad CP. Protection against late effects of radiation by 5-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 51:4125-4130 (1991).
43. Grdina DJ, Wright BJ, Carnes BA. Protection by WR-151327 against late-effect damage from fission-spectrum neutrons. Radiat Res 128:5124-5127 (1991).
44. Brown PE. Mechanism of action of aminothiol radioprotectors. Nature 213:363-364 (1967).
45. Riklis E, Kol R, Green M, Prager A, Marko R, Mintsberg M. Increased radioprotection attained by DNA repair enhancement. Pharmacol Ther 39:311-322 (1988).
46. Lowenstein E, Gleeson JL, Hecht E, Factor R, Goldfischer C, Cajigas A, Steinberg JJ. Excision repair is enhanced by WR-2721 radioprotection. In: Terrestrial Space Radiation and Its Biological Effects (McCormack PS, Swenberg CE, Brucker H, eds). New York:Plenum Press, 1989;697-714.
47. Grdina DJ, Kataoka Y, Basic I, Perrin J. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis 13:811-814 (1992).
48. Shigematsu N, Schwartz JL, Grdina DJ. Protection against radiation-induced mutagenesis at the hprt locus by spermine and N,N′-(dithio-2,1-ethanediyl)bis-1,3-propanediamine (WR-33278). Mutagenesis 9:355-360 (1994).
49. Landauer MR, Davis HD, Dominitz JA and Weiss JF. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice: WR-2721, cysteamine, diethyldithiocarbamate and N-acetylcysteine. Pharmacol Ther 39:97-100 (1988).
50. Uma Devi P, Thomas B. Bone marrow cell protection and modification of drug toxicity by combination of protectors. Pharmacol Ther 39:213-214 (1988).
51. Seifter E, Rettura G, Padawer J, Stratford F, Weinzweig J, Demetriou AA, Levenson SM. Morbidity and mortality reduction by supplemental vitamin A or β-carotene in CBA mice given total body γ-radiation. J Natl Cancer Inst 73:1167-1177 (1984).
52. Weiss JF, Srinivasan V, Kumar KS and Landauer MR. Radioprotection by metals: selenium. Adv Space Res 12(2):223-231 (1992).
53. Sarma L, Kesavan PC. Protective effects of vitamins C and E against gamma-ray-induced chromosomal damage in mouse. Int J Radiat Biol 63:759-764 (1993).
54. Emerit I, Oganesian N, Sarkisian T, Arutyunyan R, Pogosian A, Asrian K, Levy A, Cernjavski L. Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Radiat Res 144:198-205 (1995).
55. Emerit I, Quastel M, Goldsmith J, Merkin L, Levy A, Cernjavski L, Alaoui-Youssefi A, Pogosian A, Riklis E. Clastogenic factors in the plasma of children exposed at Chernobyl. Mutat Res 373:47-54 (1997).
56. Borek C, Ong A, Mason H, Donahue L, Biaglow JE. Selenium and vitamin E inhibit radiogenic and chemically induced transformation in vitro via different mechanisms. Proc Natl Acad Sci USA 83:1490-1494 (1986).
57. Kennedy AR. Prevention of radiation transformation in vitro. In:Vitamins, Nutrition and Cancer (Prasad KN, ed). Basel:Karger, 1984;166-179.
58. Bertram JS, Kolonel LN, Myskens FL. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 47:3012-3031 (1987).
59. 2 and misoprostol. Prostaglandins 33:93-104 (1987).
60. LaNasa P, Miller RC, Hanson WR, Hall EJ. Misoprostol-induced radioprotection of oncogenic transformation. Int J Radiat Oncol Biol Phys 29:273-275 (1994).
61. Ainsworth EJ. From endotoxins to newer immunomodulators: survival-promoting effects of microbial polysaccharide complexes in irradiated animals. Pharmacol Ther 39:223-241 (1988).
62. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 22:773-779 (1992).
63. Neta R, Oppenheim JJ, Douches SD. Interdependence of the radioprotective effects of human recombinant interleukin 1, tumor necrosis factor, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony stimulating factor. J Immunol 140:108-111 (1988).
64. Neta R. Insights into the mechanisms of radiation damage and radioprotection through their modulation by cytokines. Environ Health Perspect 105(Suppl 6): 1463-1465 (1997).
65. Mettler FA, Kelsey CA, Ricks RC. Medical Management of Radiation Accidents. Boca Raton, FL:CRC Press, 1990.
66. Kligerman MM, Liu T, Liu Y, Scheffler B, He S, Zhang Z. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. Int J Radiat Oncol Biol Phys 1458:1119-1122 (1992).
67. Belkac Aemi Y, Oxsahin M, Paene F, Rio B, Sutton L, Laporte JP, Touboul E, Gorin NC, Laugier A. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiat Oncol Biol Phys 36:77-82 (1996).
68. Consensus Report on the Use of the Radioprotector Ethyol® (amifostine) for Planned Radiation Exposures during Emergencies. Oak Ridge, TN:REAC/TS, Oak Ridge Institute for Science and Education, September 1996.
69. Constine LS, Zagars G, Rubin P, Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 12:1505-1508 (1986).
70. Coia L, Krigel R, Hanks G, Comis R, Algazy K, Peters R, McCulloch W, Schein P. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies. Im J Radiat Oncol Biol Phys 22:791-794 (1992).
71. Washburn LC, Rafter JI, Hayes RL, Yuhas JM. Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res 66:100-105 (1976).